Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
2 December 2015
E-015334-15
Question for written answer
to the Commission
Rule 130
Ian Duncan (ECR)

 Subject:  Pre-exposure prophylaxis (PrEP) for HIV
 Answer(s) 

In September 2015, the World Health Organisation (WHO) issued guidance on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. The guidance concludes that the use of daily oral pre-exposure prophylaxis (PrEP) is recommended as a prevention choice for people at substantial risk of contracting HIV infection as part of a combination of prevention approaches.

Currently, there is no coordinated approach at EU level for the use of PrEP within the Member States. Some Member States, like Belgium, have initiated trials into the efficacy of using PrEP, and in some like the UK, PrEP is available through private health practitioners.

Given the recent WHO guidance, will the Commission consider releasing its own recommendations on the use of PrEP throughout the Member States and in so doing bolster the early prevention of HIV among people at substantial risk?

Last updated: 9 February 2016Legal notice